About this approach
Tumor Treating Fields (TTFields) are a noninvasive, device-based cancer treatment. Adhesive arrays placed on the shaved scalp or skin deliver low-intensity, alternating electric fields to a defined tumor region. The fields are designed to interfere with cancer-cell division. Treatment is delivered for many hours each day at home and is usually combined with specific medicines. TTFields are different from radiation therapy, electrical tumor ablation, TENS, and implanted stimulation devices.
Where it fits: FDA-approved device treatment for defined glioblastoma, malignant pleural mesothelioma, metastatic non-small cell lung cancer, and locally advanced pancreatic cancer settings
Where this treatment is used
TTFields evidence is diagnosis- and regimen-specific. In newly diagnosed supratentorial glioblastoma, the EF-14 randomized trial found that adding TTFields to maintenance temozolomide improved median progression-free survival from 4.0 to 6.7 months and median overall survival from 16.0 to 20.9 months. U.S. device indications also include recurrent glioblastoma, unresectable locally advanced or metastatic malignant pleural mesothelioma with pemetrexed and platinum chemotherapy, metastatic non-small cell lung cancer that progressed on or after platinum therapy with a PD-1/PD-L1 inhibitor or docetaxel, and locally advanced pancreatic cancer with gemcitabine and nab-paclitaxel.
Procedure and practical considerations
Skin reactions beneath the arrays are the most common device-related problem and can include redness, itching, pain, warmth, infection, skin breakdown, or ulceration. The equipment, frequent array changes, skin preparation, and long daily wear schedule can affect sleep, mobility, work, body image, and travel. Device labels include diagnosis-specific contraindications, warnings, and precautions, including considerations involving implanted electronic devices, skull defects or replacement materials, pregnancy, and sensitivity to conductive gels or adhesives.
Alternating electric fields are delivered through skin arrays
A portable generator sends low-intensity, intermediate-frequency alternating electric fields through insulated adhesive arrays. The array layout and frequency depend on the tumor location and device. TTFields are intended to disrupt processes needed during cancer-cell division; the treatment does not heat or destroy tissue in the same way as thermal ablation and does not use ionizing radiation.
A wearable treatment that becomes part of everyday life
A trained patient or caregiver replaces the arrays on a regular schedule, prepares the skin, connects the generator, charges batteries, and carries the device in a bag or backpack. Programs generally emphasize long daily use because exposure time is part of the treatment plan. The exact goal and handling instructions come from the current device label and prescribing team.
- Ask for a hands-on demonstration before the first home array change.
- Plan clothing, sleep, work, exercise, travel, and charging around the device.
- Report skin changes early; small problems are often easier to manage before they interrupt treatment.
- Keep scheduled imaging and oncology visits because the device does not replace disease monitoring.
The device and accompanying medicines depend on the cancer
- Newly diagnosed supratentorial glioblastoma: Optune Gio with maintenance temozolomide after surgery and chemoradiation, for patients who meet the device label.
- Recurrent supratentorial glioblastoma: Optune Gio as monotherapy in the defined recurrent setting after prior chemotherapy, when surgical and radiation options have been exhausted.
- Unresectable, locally advanced or metastatic malignant pleural mesothelioma: Optune Lua with pemetrexed and platinum-based chemotherapy.
- Metastatic non-small cell lung cancer that progressed on or after a platinum regimen: Optune Lua with a PD-1/PD-L1 inhibitor or docetaxel.
- Locally advanced pancreatic cancer: Optune Pax with gemcitabine and nab-paclitaxel.
Benefit estimates cannot be transferred between diagnoses
The strongest evidence and regulatory decision for each use come from a specific patient population, device configuration, frequency, accompanying regimen, and clinical trial. A clinic should be able to identify the exact indication or trial protocol it is following. Use for a different cancer, stage, body region, or drug combination should be described as investigational rather than presented as an established extension of another indication.
Good skin care helps patients stay on treatment
Array placement rotates across the treatment area to reduce repeated pressure and irritation. Programs may recommend careful shaving or hair removal, dry skin before application, inspection at each change, and diagnosis-specific products for mild reactions. Broken skin, drainage, spreading redness, fever, significant pain, or suspected infection needs prompt clinical advice.
Look for a team that supports both oncology and device logistics
- A prescriber experienced with the exact diagnosis and current device label.
- A documented process for array-layout planning and updates after imaging.
- Rapid help for skin reactions, alarms, equipment failure, and replacement supplies.
- Clear coordination with medical oncology, radiation oncology, surgery, and local care teams.
- Up-front explanation of coverage, prior authorization, travel, training, and ongoing supply costs.
Clinics reporting this approach
These clinic profiles connect to this approach through clinic-confirmed selections or Cancer Clinic Finder’s source review. Open a profile to compare locations, services, practical details, and ways to get started.
Sources
Source information checked: 2026-10-07. The links below identify the public and clinic-provided materials used for this page.
Compiled by: Cancer Clinic Finder Editorial Team
- FDA: Optune Gio approval for newly diagnosed and recurrent glioblastoma ↗Checked 2026-10-07
- JAMA / PubMed: EF-14 randomized trial of TTFields plus temozolomide in newly diagnosed glioblastoma ↗Checked 2026-10-07
- FDA: Optune Lua for unresectable locally advanced or metastatic malignant pleural mesothelioma ↗Checked 2026-10-07
- FDA: Optune Lua for metastatic non-small cell lung cancer ↗Checked 2026-10-07
- FDA: Optune Pax approval for locally advanced pancreatic cancer ↗Checked 2026-10-07
- PubMed: health-related quality of life during TTFields treatment in EF-14 ↗Checked 2026-10-07
How Cancer Clinic Finder compiles information · Suggest a factual correction